GlassScriptPhysician profile
Federico Pichardo
NPI 1821213448
$15,673.55
in general payments reported to CMS, 2019-2025
46 companies · $3,606 in 2025
The $3,606 reported for 2025 was more than what 97% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,581 · 2022: $2,803 · 2023: $2,798 · 2024: $2,886 · 2025: $3,606.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,290.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,289.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,234.43 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,844.88 | 2021-2025 | Xifaxan, Trulance, Relistor |
| Novo Nordisk INC | $1,523.41 | 2021-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $1,258.50 | 2021-2025 | Lokelma, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,079.42 | 2021-2025 | Jardiance |
| Biohaven Pharmaceuticals, INC. | $931.28 | 2021 | |
| Intra-Sana Laboratories | $553.62 | 2023-2025 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Ardelyx, INC. | $507.14 | 2022-2025 | Ibsrela |
| E.R. Squibb & Sons, L.L.C. | $486.79 | 2021-2024 | Camzyos, Eliquis |
| Astellas Pharma US INC | $461.90 | 2021-2024 | Veozah, Myrbetriq |
| Glaxosmithkline, LLC. | $449.25 | 2021-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Xeris Pharmaceuticals, INC. | $368.68 | 2024-2025 | Recorlev, Gvoke Hypopen |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $361.75 | 2024-2025 | Caplyta |
| Novartis Pharmaceuticals Corporation | $337.91 | 2022-2025 | |
| Daiichi Sankyo INC. | $328.77 | 2022-2024 | Injectafer |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $323.64 | 2021-2022 | |
| Amgen INC. | $315.94 | 2021-2025 | Otezla, Repatha, Repatha |
| Pfizer INC. | $242.86 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $242.82 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $189.83 | 2023-2025 | Rexulti |
| Horizon Therapeutics Plc | $180.92 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $173.87 | 2022-2024 | Austedo Xr, Austedo |
| Insulet Corporation | $164.64 | 2025 | Omnipod |
| Lundbeck LLC | $121.27 | 2022-2025 | Rexulti |
| Lilly USA, LLC | $110.05 | 2021-2024 | Mounjaro, Zepbound |
| Ironwood Pharmaceuticals, INC | $92.13 | 2021-2023 | Linzess |
| Mylan Specialty L.P. | $90.12 | 2023 | Yupelri |
| Kowa Pharmaceuticals America, INC. | $70.93 | 2021-2025 | Zoryve |
| Nevro Corp. | $68.94 | 2021 | |
| Esperion Therapeutics, INC. | $67.63 | 2021-2023 | Nexletol |
| Sanofi-Aventis U.S. LLC | $54.48 | 2021-2022 | |
| Genentech USA, INC. | $53.50 | 2021-2022 | |
| Nestle Healthcare Nutrition INC. | $45.14 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $44.99 | 2022 | |
| Aimmune Therapeutics, INC. | $39.34 | 2024-2025 | Zenpep |
| Corium, LLC | $35.83 | 2022-2023 | Adlarity |
| Mannkind Corporation | $33.98 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $32.90 | 2022 | |
| Vanda Pharmaceuticals INC. | $24.92 | 2024 | Fanapt, Hetlioz |
| Vivus LLC | $20.21 | 2025 | Pancreaze |
| Merck Sharp & Dohme LLC | $20.21 | 2021 | |
| Biogen, INC. | $19.56 | 2025 | Leqembi |
| Amarin Pharma, INC. | $17.90 | 2021 | |
| Phathom Pharmaceuticals, INC. | $17.44 | 2024 | Voquezna |
| Redhill Biopharma INC. | $16.63 | 2021 | |
| Phadia US INC. | $13.20 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Federico Pichardo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.